Your search for ‘Smart & Biggar’ returned 2,497 results

JUBLIA (efinaconazole): Bausch Health and Valeant Canada v Pharmascience.

Following two public consultations with stakeholders, the Government of Ontario (Ministry of Finance) is moving forward with legislation to regulate preferred provider networks (PPNs).

The PMPRB recently decided to adopt its Amended Interim Guidance, effective immediately (see our firm's article on the amendments here). The Amended Interim Guidance indicates...

The report provides an overview of the market for EDRDs, including a comparison between Canada and PMPRB comparator countries.

In a decision rendered on August 17, 2022, the Federal Court granted Sandoz Canada Inc (Sandoz) leave to amend its Statement of Defence to add new allegations...

Santé Canada a publié ses rapports trimestriels pour les deuxième et troisième trimestres de 2025-2026, présentant des données détaillées sur les délais de traitement des demandes d'autorisation de mise en marché d'instruments médicaux.

Data transparency is becoming a priority for life sciences research. It is a good time for Canadian researchers to refresh themselves on best practices when it comes to data sharing.

Bill C-4, entitled An Act to implement the Agreement between Canada, the United States of America and the United Mexican States was tabled in the Parliament of Canada on January 29, 2020.

The vast majority of IP litigants in Canada already make the Federal Court their choice of forum.

After three years, any registration can be cancelled for non-use, thus deterring plaintiffs from relying on registrations for marks that are not in use.

Prior to January 17, 2020, extensions of time were readily available during Canadian trademark prosecution. A single six-month extension could be secured without providing any substantive reasons.

Trademark practitioners in Canada know that consent agreements between a trademark applicant and the owner of a cited trademark are not easily accepted by the Trademarks Office (TMO).

Several patent offices have launched a "Collaborative Search and Examination" Pilot Project ("CS&E"), which will allow examiners from key patent offices to collaborate on examination of PCT Applications.

A person can be liable for patent infringement when he or she makes a product that includes all the features found in the patent’s claim or claims

During a bankruptcy or a restructuring, the goal of bankruptcy law is at odds with the goal of intellectual property law.

Civil contempt of court proceedings are quasi-criminal in nature.

The College of Patent Agents & Trademark Agents (CPATA) recently issued an alert regarding a surge in fraudulent emails targeting trademark owners. As is typical of these "phishing" scams, the emails often pressure...

Over the past several years, the environment for pharmaceutical patents in Canada has improved significantly.